Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS004 + Toripalimab + Chemotherapy in Esophageal Squamous Cell Carcinoma
NCT06588335Phase 2Not yet recruiting
- Sponsor
- Henan Provincial People's Hospital
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of tifcemalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Henan Provincial People's Hospital. Primary endpoint: Pathological Complete Response Rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
tifcemalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06588335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588335.